Pieter Hendrik Reitsma

This inventor holds 12 USPTO granted patents and 12 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Academisch Ziekenhuis Leiden, Celera Corporation, Rijksuniversiteit Leiden. Active years: 1999-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pieter Hendrik Reitsma. Retrieved from https://idiyas.com/inventor/pieter-hendrik-reitsma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 12)

% Patents Active = 83.3

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 2.9

ph-index = 3

Forward Citations = 37(Granted Patents)

Location History:

Alameda, CA (US) (2011)
TJ Leiden, NL (2011 - 2012)
Leiden, NL (1999 - 2024)

Company Filing History:

4 out of 47

Academisch Ziekenhuis Leiden

Rijksuniversiteit Leiden

Lieden University Medical Center (Lumc)

patent

where one patent can have more than one assignee

Years Active: 1999-2024

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12083170 - Prohemostatic proteins for the treatment of bleeding (2024-09-10),

2. 11357836 - Prohemostatic proteins for the treatment of bleeding (2022-06-14),

3. 11304995 - Prohemostatic proteins for the treatment of bleeding (2022-04-19),

4. 11124834 - Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof (2021-09-21),

5. 10537618 - Prohemostatic proteins for the treatment of bleeding (2020-01-21),

6. 8227189 - Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof (2012-07-24),

7. 8071291 - Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof (2011-12-06),

8. 7910303 - Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof (2011-03-22),

9. 6558913 - Method for screening for the presence of genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein C (2003-05-06),

10. 6518016 - Method for diagnosing an increased risk for thrombosis or a genetic defect causing thrombosis and kit for use with the same (2003-02-11),

11. 5910576 - Method for screening for the presence of a genetic defect associated (1999-06-08),

12. 5874256 - Method for diagnosing an increased risk for thrombosis or a genetic (1999-02-23),

Title: Innovations of Pieter Hendrik Reitsma

Introduction

Pieter Hendrik Reitsma is a notable inventor based in Leiden, Netherlands. He has made significant contributions to the field of biomedicine, particularly in the development of prohemostatic proteins. With a total of 12 patents to his name, Reitsma's work focuses on advancing treatments for bleeding disorders.

Latest Patents

Reitsma's latest patents include innovative recombinant FXa polypeptides designed to treat bleeding. These polypeptides serve as antidotes that can completely or partially reverse the anticoagulant effects of coagulation inhibitors, particularly direct factor Xa inhibitors. His disclosures detail methods for utilizing recombinant factor Xa proteins to achieve these therapeutic effects.

Career Highlights

Throughout his career, Reitsma has worked with prominent organizations such as Celera Corporation and Academisch Ziekenhuis Leiden. His experience in these institutions has allowed him to refine his expertise in the development of medical innovations.

Collaborations

Some of Reitsma's notable coworkers include Lance Bare and James J Devlin. Their collaborative efforts have contributed to the advancement of research in the field of coagulation and hemostasis.

Conclusion

Pieter Hendrik Reitsma's contributions to medical science through his patents and collaborations highlight his role as a leading inventor in the field of prohemostatic treatments. His work continues to pave the way for advancements in therapeutic options for patients with bleeding disorders.

Profile summary based on public USPTO records.